Loading...

Development and characterization of novel anti‐C5 monoclonal antibodies capable of inhibiting complement in multiple species

Over the last decade there has been an explosion in complement therapies; one‐third of the drugs in the clinic or in development target C5 protein. Eculizumab, a monoclonal antibody (mAb) that binds C5 and blocks its cleavage by the convertase, is the current reference standard treatment for atypica...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Immunology
Main Authors: Zelek, Wioleta M., Taylor, Philip R., Morgan, B. Paul
Format: Artigo
Sprog:Inglês
Udgivet: John Wiley and Sons Inc. 2019
Fag:
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6620185/
https://ncbi.nlm.nih.gov/pubmed/31120547
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/imm.13083
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!